TY  - CONF
AU  - Roganović, Maša
AU  - Stanojković, Tatjana
AU  - Nikitović, Marina
AU  - Petrović, Nina
AU  - Đurić, Ana
AU  - Matić, Ivana
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4899
AB  - Introduction: The second most common form of cancer in the male population is prostate cancer. Therapeutic options include radical prostatectomy, different forms of radiotherapy, hormone treatment and chemotherapy. Radical prostatectomy and radiotherapy are the most frequently used strategies and enable a long survival for patients diagnosed on time. Because of the prostate anatomy, patients that are on radiotherapy experience a great range of side effects, and even after the therapy is finished, side effects such as urogenital and gastrointestinal toxicity can persist for years. Although survival is long regardless of the therapeutic option used, choosing the appropriate therapeutic options for the patients in terms of efficacy and safety is very important [1]. 

Objectives: We aimed in developing a model for repeated count data, i.e. fatigue, which is the most common adverse event that patients experience during radiotherapy. In addition, the objective of the study is to assess the effect of various covariates on the probability of the event happening using different modelling approaches [2]. 

Methods: Data collected from prostate cancer patients included: age, concentrations of glutamine and glutamate before radiotherapy and after 5, 15, 25 and 30 fractions of radiotherapy, as well as a month after the last fraction of radiotherapy (first follow – up visit), genetic testing results regarding variants in glutamine metabolic pathway, signs and symptoms of acute or chronic urogenital and gastrointestinal toxicity, fatigue, details of their treatment (e.g. radical prostatectomy, hormone therapy), their smoking and alcohol intake status, presence of hypertension or diabetes mellitus type II, and other laboratory findings of significance. Analysis was performed using nonlinear mixed effects modelling approach using NONMEM® software (version 7.4). We tested two approaches: modelling using the first-order estimation method and the Laplace method of estimation in order to create a Poisson model for count data. NONMEM outputs were handled in R software (graphical diagnostics). Model evaluation has been performed using numerical and visual approaches. Covariate model building was performed using a stepwise covariate procedure (SCM). Covariates that were tested are age, glutamine/glutamate concentrations (continuous, time-varying covariates). The influence of categorical covariates was also examined (smoking and alcohol intake, presence of aforementioned comorbidities). 

Results: In total, we analysed 143 data records from 28 male patients aged 53-82 years (mean±sd: 72.67±6.64), mainly older people (>65 years old) that were included in the analysis. The probability of fatigue occurrence was 78.3%, which was rather high but expected. The objective function value of the developed base model using the Laplace method of estimation was 546.346. The average number of fatigue events occurring in the period from the start of the radiotherapy until the first follow-up visit was estimated to be 2.48 with a 95% confidence interval of 1.655 - 3.305 and RSE of 17%. Interindividual variability in the number of fatigue events per patient was estimated at 48.3%, with a shrinkage of 11.1%. The inclusion of the covariates in the base model did not improve the model fit, so they were not kept in the model. 

Conclusion: Our results confirm that fatigue is one of the most common side effects of radiotherapy. Although our model did not show that examined covariates have an effect on the average number of fatigue events,  further analysis will aim at testing different modelling approaches when it comes to modelling side effects of radiotherapy in order to minimize them in cancer patients. 



[1] Retrieved from https://www.nhs.uk/conditions/prostate-cancer/treatment/ . Last access: 19.3.2023.
[2] Plan E.L. Modeling and simulation of count data.  CPT Pharmacometrics Syst. Pharmacol. 2014: 3 (8): p. e129.
C3  - Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe
T1  - Modelling fatigue events in prostate cancer patients on radiotherapy
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4899
ER  - 

@conference{
author = "Roganović, Maša and Stanojković, Tatjana and Nikitović, Marina and Petrović, Nina and Đurić, Ana and Matić, Ivana and Jovanović, Marija and Vučićević, Katarina",
year = "2023",
abstract = "Introduction: The second most common form of cancer in the male population is prostate cancer. Therapeutic options include radical prostatectomy, different forms of radiotherapy, hormone treatment and chemotherapy. Radical prostatectomy and radiotherapy are the most frequently used strategies and enable a long survival for patients diagnosed on time. Because of the prostate anatomy, patients that are on radiotherapy experience a great range of side effects, and even after the therapy is finished, side effects such as urogenital and gastrointestinal toxicity can persist for years. Although survival is long regardless of the therapeutic option used, choosing the appropriate therapeutic options for the patients in terms of efficacy and safety is very important [1]. 

Objectives: We aimed in developing a model for repeated count data, i.e. fatigue, which is the most common adverse event that patients experience during radiotherapy. In addition, the objective of the study is to assess the effect of various covariates on the probability of the event happening using different modelling approaches [2]. 

Methods: Data collected from prostate cancer patients included: age, concentrations of glutamine and glutamate before radiotherapy and after 5, 15, 25 and 30 fractions of radiotherapy, as well as a month after the last fraction of radiotherapy (first follow – up visit), genetic testing results regarding variants in glutamine metabolic pathway, signs and symptoms of acute or chronic urogenital and gastrointestinal toxicity, fatigue, details of their treatment (e.g. radical prostatectomy, hormone therapy), their smoking and alcohol intake status, presence of hypertension or diabetes mellitus type II, and other laboratory findings of significance. Analysis was performed using nonlinear mixed effects modelling approach using NONMEM® software (version 7.4). We tested two approaches: modelling using the first-order estimation method and the Laplace method of estimation in order to create a Poisson model for count data. NONMEM outputs were handled in R software (graphical diagnostics). Model evaluation has been performed using numerical and visual approaches. Covariate model building was performed using a stepwise covariate procedure (SCM). Covariates that were tested are age, glutamine/glutamate concentrations (continuous, time-varying covariates). The influence of categorical covariates was also examined (smoking and alcohol intake, presence of aforementioned comorbidities). 

Results: In total, we analysed 143 data records from 28 male patients aged 53-82 years (mean±sd: 72.67±6.64), mainly older people (>65 years old) that were included in the analysis. The probability of fatigue occurrence was 78.3%, which was rather high but expected. The objective function value of the developed base model using the Laplace method of estimation was 546.346. The average number of fatigue events occurring in the period from the start of the radiotherapy until the first follow-up visit was estimated to be 2.48 with a 95% confidence interval of 1.655 - 3.305 and RSE of 17%. Interindividual variability in the number of fatigue events per patient was estimated at 48.3%, with a shrinkage of 11.1%. The inclusion of the covariates in the base model did not improve the model fit, so they were not kept in the model. 

Conclusion: Our results confirm that fatigue is one of the most common side effects of radiotherapy. Although our model did not show that examined covariates have an effect on the average number of fatigue events,  further analysis will aim at testing different modelling approaches when it comes to modelling side effects of radiotherapy in order to minimize them in cancer patients. 



[1] Retrieved from https://www.nhs.uk/conditions/prostate-cancer/treatment/ . Last access: 19.3.2023.
[2] Plan E.L. Modeling and simulation of count data.  CPT Pharmacometrics Syst. Pharmacol. 2014: 3 (8): p. e129.",
journal = "Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe",
title = "Modelling fatigue events in prostate cancer patients on radiotherapy",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4899"
}

Roganović, M., Stanojković, T., Nikitović, M., Petrović, N., Đurić, A., Matić, I., Jovanović, M.,& Vučićević, K.. (2023). Modelling fatigue events in prostate cancer patients on radiotherapy. in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
https://hdl.handle.net/21.15107/rcub_farfar_4899

Roganović M, Stanojković T, Nikitović M, Petrović N, Đurić A, Matić I, Jovanović M, Vučićević K. Modelling fatigue events in prostate cancer patients on radiotherapy. in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4899 .

Roganović, Maša, Stanojković, Tatjana, Nikitović, Marina, Petrović, Nina, Đurić, Ana, Matić, Ivana, Jovanović, Marija, Vučićević, Katarina, "Modelling fatigue events in prostate cancer patients on radiotherapy" in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4899 .

TY  - CONF
AU  - Roganović, Maša
AU  - Cvetković, Mirjana
AU  - Gojković, Ivana
AU  - Spasojević, Brankica
AU  - Kostić, Mirjana
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4532
AB  - Cyclosporin A (CyA) is an immunosuppressant used as part of a post-transplant
therapeutic protocol to prevent graft rejection. Due to the large pharmacokinetic variability
that characterizes it, it is necessary to conduct therapeutic drug monitoring (TDM). The aim
of the conducted research is to assess the exposure of CyA in the period of up to 3 months
after transplantation (early post-transplantation period) with the identification of factors
that influence the values of the pharmacokinetic parameters of CyA. From pediatric patients
with kidney transplants, at the University Children ́s Hospital Tiršova, data about dosage
regimens, cotherapy, and measured CyA concentrations (C0 - immediately before the next
dose and C2 - 2 hours after the morning dose) were collected retrospectively. Data were
analysed in NONMEM® (version 7.4). Twenty six patients (up to 12 years old) were
included in the analysis. The pharmacokinetic model that best described the data is a one-
compartment model with first-order absorption. Haematocrit, serum creatinine and body
mass were identified as the main factors of variability. In further analysis, it is necessary to
include data about genetic polymorphism, which is expected to have the greatest impact on
drug exposure and change the power ratio of factors that influence CyA parameter values
and concentrations.The obtained results are expected considering the characteristics of CyA.
In addition to identification, quantification of the influence of the mentioned factors is crucial
for establishing an optimal dosing regimen in the early post-transplantation period in
children, when the risk of graft rejection is the highest.
AB  - Ciklosporin A (CyA) je imunosupresiv koji se koristi kao deo posttransplantacionog
terapijskog protokola u cilju prevencije odbacivanja grafta. Zbog velike farmakokinetičke
varijabilnosti koja ga karakteriše, neophodno je sprovođenje terapijskog monitoringa
(therapeutic drug monitoring, TDM). Cilj sprovedenog istraživanja je procena izloženosti CyA
u periodu do 3 meseca nakon transplantacije (rani posttransplantacioni period) uz
identifikaciju faktora koji utiču na vrednosti farmakokinetičkih parametara CyA. Od
pedijatrijskih pacijenata sa transplantiranim bubregom, u Univerzitetskoj klinici Tiršova,
retrospektivno su prikupljani podaci o primenjenoj dozi CyA, koterapiji, izmerenim
koncentracijama CyA (C0 – neposredno pred davanje naredne doze i C2 – 2 sata nakon
jutarnje doze) i vrednostima laboratorijskih parametara od značaja. Podaci su obrađivani
upotrebom populacione farmakokinetičke analize u programu NONMEM® (verzija 7.4). U
analizu je uključeno 26 pacijenata starosti do 12 godina. Farmakokinetički model koji
najbolje opisuje dostupne podatke je jednoprostorni model sa apsorpcijom prvog reda. Kao
glavni faktori varijabilnosti identifikovani su hematokrit, serumski kreatinin i telesna masa.
U daljoj analizi, neophodno je uključiti podatke o genetskom polimorfizmu, za koje se
očekuje da će imati najveći uticaj na izloženost leku i promeniti odnos snaga faktora koji
utiču na vrednosti parametara CyA i koncentraciju. Dobijeni rezultati su očekivani imajući u
vidu karakteristike CyA. Pored identifikacije, i kvantifikacija uticaja navedenih faktora je
ključna za uspostavljanje optimalnog režima doziranja u ranom posttransplantacionom
periodu kod dece, kada je rizik od odbacivanja grafta najveći.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Assessment of cyclosporin A exposure and identification of variability factors in the early posttransplantation period
T1  - Procena izloženosti ciklosporinu a i identifikacija faktora varijabilnosti u ranom posttransplantacionom periodu
VL  - 72
IS  - 4 suplement
SP  - S304
EP  - S305
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4532
ER  - 

@conference{
author = "Roganović, Maša and Cvetković, Mirjana and Gojković, Ivana and Spasojević, Brankica and Kostić, Mirjana and Miljković, Branislava and Vučićević, Katarina",
year = "2022",
abstract = "Cyclosporin A (CyA) is an immunosuppressant used as part of a post-transplant
therapeutic protocol to prevent graft rejection. Due to the large pharmacokinetic variability
that characterizes it, it is necessary to conduct therapeutic drug monitoring (TDM). The aim
of the conducted research is to assess the exposure of CyA in the period of up to 3 months
after transplantation (early post-transplantation period) with the identification of factors
that influence the values of the pharmacokinetic parameters of CyA. From pediatric patients
with kidney transplants, at the University Children ́s Hospital Tiršova, data about dosage
regimens, cotherapy, and measured CyA concentrations (C0 - immediately before the next
dose and C2 - 2 hours after the morning dose) were collected retrospectively. Data were
analysed in NONMEM® (version 7.4). Twenty six patients (up to 12 years old) were
included in the analysis. The pharmacokinetic model that best described the data is a one-
compartment model with first-order absorption. Haematocrit, serum creatinine and body
mass were identified as the main factors of variability. In further analysis, it is necessary to
include data about genetic polymorphism, which is expected to have the greatest impact on
drug exposure and change the power ratio of factors that influence CyA parameter values
and concentrations.The obtained results are expected considering the characteristics of CyA.
In addition to identification, quantification of the influence of the mentioned factors is crucial
for establishing an optimal dosing regimen in the early post-transplantation period in
children, when the risk of graft rejection is the highest., Ciklosporin A (CyA) je imunosupresiv koji se koristi kao deo posttransplantacionog
terapijskog protokola u cilju prevencije odbacivanja grafta. Zbog velike farmakokinetičke
varijabilnosti koja ga karakteriše, neophodno je sprovođenje terapijskog monitoringa
(therapeutic drug monitoring, TDM). Cilj sprovedenog istraživanja je procena izloženosti CyA
u periodu do 3 meseca nakon transplantacije (rani posttransplantacioni period) uz
identifikaciju faktora koji utiču na vrednosti farmakokinetičkih parametara CyA. Od
pedijatrijskih pacijenata sa transplantiranim bubregom, u Univerzitetskoj klinici Tiršova,
retrospektivno su prikupljani podaci o primenjenoj dozi CyA, koterapiji, izmerenim
koncentracijama CyA (C0 – neposredno pred davanje naredne doze i C2 – 2 sata nakon
jutarnje doze) i vrednostima laboratorijskih parametara od značaja. Podaci su obrađivani
upotrebom populacione farmakokinetičke analize u programu NONMEM® (verzija 7.4). U
analizu je uključeno 26 pacijenata starosti do 12 godina. Farmakokinetički model koji
najbolje opisuje dostupne podatke je jednoprostorni model sa apsorpcijom prvog reda. Kao
glavni faktori varijabilnosti identifikovani su hematokrit, serumski kreatinin i telesna masa.
U daljoj analizi, neophodno je uključiti podatke o genetskom polimorfizmu, za koje se
očekuje da će imati najveći uticaj na izloženost leku i promeniti odnos snaga faktora koji
utiču na vrednosti parametara CyA i koncentraciju. Dobijeni rezultati su očekivani imajući u
vidu karakteristike CyA. Pored identifikacije, i kvantifikacija uticaja navedenih faktora je
ključna za uspostavljanje optimalnog režima doziranja u ranom posttransplantacionom
periodu kod dece, kada je rizik od odbacivanja grafta najveći.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Assessment of cyclosporin A exposure and identification of variability factors in the early posttransplantation period, Procena izloženosti ciklosporinu a i identifikacija faktora varijabilnosti u ranom posttransplantacionom periodu",
volume = "72",
number = "4 suplement",
pages = "S304-S305",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4532"
}

Roganović, M., Cvetković, M., Gojković, I., Spasojević, B., Kostić, M., Miljković, B.,& Vučićević, K.. (2022). Assessment of cyclosporin A exposure and identification of variability factors in the early posttransplantation period. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S304-S305.
https://hdl.handle.net/21.15107/rcub_farfar_4532

Roganović M, Cvetković M, Gojković I, Spasojević B, Kostić M, Miljković B, Vučićević K. Assessment of cyclosporin A exposure and identification of variability factors in the early posttransplantation period. in Arhiv za farmaciju. 2022;72(4 suplement):S304-S305.
https://hdl.handle.net/21.15107/rcub_farfar_4532 .

Roganović, Maša, Cvetković, Mirjana, Gojković, Ivana, Spasojević, Brankica, Kostić, Mirjana, Miljković, Branislava, Vučićević, Katarina, "Assessment of cyclosporin A exposure and identification of variability factors in the early posttransplantation period" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S304-S305,
https://hdl.handle.net/21.15107/rcub_farfar_4532 .

TY  - CONF
AU  - Marković, Aleksandra
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4391
AB  - Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema.
AB  - Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća
T1  - Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease
VL  - 72
IS  - 4-suplement
SP  - S282
EP  - S283
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4391
ER  - 

@conference{
author = "Marković, Aleksandra and Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema., Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća, Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease",
volume = "72",
number = "4-suplement",
pages = "S282-S283",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4391"
}

Marković, A., Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391

Marković A, Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju. 2022;72(4-suplement):S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

Marković, Aleksandra, Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S282-S283,
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

TY  - CONF
AU  - Lazarević, Katarina
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4390
AB  - Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi.
AB  - Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti
T1  - Review of therapy and therapeutic problems in patients with asthma in primary health care
VL  - 72
IS  - 4-suplement
SP  - S280
EP  - S281
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4390
ER  - 

@conference{
author = "Lazarević, Katarina and Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi., Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti, Review of therapy and therapeutic problems in patients with asthma in primary health care",
volume = "72",
number = "4-suplement",
pages = "S280-S281",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4390"
}

Lazarević, K., Kovačević, M., Ćulafić, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390

Lazarević K, Kovačević M, Ćulafić M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4-suplement):S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

Lazarević, Katarina, Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S280-S281,
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Milenković, Branislava
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4388
AB  - Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici.
AB  - Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak
T1  - Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers
VL  - 72
IS  - 4-suplement
SP  - S274
EP  - S275
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4388
ER  - 

@conference{
author = "Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Milenković, Branislava and Miljković, Branislava",
year = "2022",
abstract = "Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici., Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak, Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers",
volume = "72",
number = "4-suplement",
pages = "S274-S275",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4388"
}

Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vučićević, K., Vezmar-Kovačević, S., Milenković, B.,& Miljković, B.. (2022). Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388

Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vučićević K, Vezmar-Kovačević S, Milenković B, Miljković B. Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju. 2022;72(4-suplement):S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Milenković, Branislava, Miljković, Branislava, "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S274-S275,
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

TY  - CONF
AU  - Homšek, Ana
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4387
AB  - Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima.
AB  - Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti
T1  - Pharmacists’ perception about providing services to patients with headaches in primary care
VL  - 72
IS  - 4 suplement
SP  - S264
EP  - S265
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4387
ER  - 

@conference{
author = "Homšek, Ana and Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima., Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti, Pharmacists’ perception about providing services to patients with headaches in primary care",
volume = "72",
number = "4 suplement",
pages = "S264-S265",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4387"
}

Homšek, A., Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387

Homšek A, Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vezmar-Kovačević S, Vučićević K, Miljković B. Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

Homšek, Ana, Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S264-S265,
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4396
AB  - Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije.
AB  - Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima
T1  - Concerns about medications in patients with chronic respiratory disease
VL  - 72
IS  - 4 Suplement
SP  - S256
EP  - S257
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4396
ER  - 

@conference{
author = "Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije., Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima, Concerns about medications in patients with chronic respiratory disease",
volume = "72",
number = "4 Suplement",
pages = "S256-S257",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4396"
}

Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396

Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju. 2022;72(4 Suplement):S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S256-S257,
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4386
AB  - Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu.
AB  - The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti
T1  - Frequency of benzodiazepine use in elderly primary care patients
VL  - 72
IS  - 4 suplement
SP  - S258
EP  - S259
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4386
ER  - 

@conference{
author = "Kovačević, Milena and Jovanović, Marija and Ćulafić, Milica and Roganović, Maša and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu., The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti, Frequency of benzodiazepine use in elderly primary care patients",
volume = "72",
number = "4 suplement",
pages = "S258-S259",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4386"
}

Kovačević, M., Jovanović, M., Ćulafić, M., Roganović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386

Kovačević M, Jovanović M, Ćulafić M, Roganović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

Kovačević, Milena, Jovanović, Marija, Ćulafić, Milica, Roganović, Maša, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S258-S259,
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

TY  - JOUR
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4383
AB  - COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.
PB  - Polish Pharmaceutical Society
T2  - Acta Poloniae Pharmaceutica - Drug Research
T1  - Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status
VL  - 79
IS  - 5
SP  - 725
EP  - 734
DO  - 10.32383/appdr/155353
ER  - 

@article{
author = "Ćulafić, Milica and Kovačević, Milena and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.",
publisher = "Polish Pharmaceutical Society",
journal = "Acta Poloniae Pharmaceutica - Drug Research",
title = "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status",
volume = "79",
number = "5",
pages = "725-734",
doi = "10.32383/appdr/155353"
}

Ćulafić, M., Kovačević, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research
Polish Pharmaceutical Society., 79(5), 725-734.
https://doi.org/10.32383/appdr/155353

Ćulafić M, Kovačević M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research. 2022;79(5):725-734.
doi:10.32383/appdr/155353 .

Ćulafić, Milica, Kovačević, Milena, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status" in Acta Poloniae Pharmaceutica - Drug Research, 79, no. 5 (2022):725-734,
https://doi.org/10.32383/appdr/155353 . .

TY  - JOUR
AU  - Homšek, Ana
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Jovanović, Marija
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4376
AB  - Thyroid dysfunction is one of the most prevalent endocrine disorders, especially common
in female patients. If patients are not diagnosed in time or adequately treated, the patients’ quality
of life can be significantly impaired and additional health problems may occur, considering the
key roles of thyroid hormones in the body. Therefore, it is necessary to raise awareness about the
importance of recognition of symptoms that may indicate a potential problem with the thyroid
gland and help to identify possible causes. For patients who are already being treated with
levothyroxine (hypothyroidism), or thiamazole, carbimazole or propylthiouracil
(hyperthyroidism), it is necessary to point out the necessity of proper, regular use of the drugs and
implementation of accompanying nonpharmacological measures, as well as the potential for the
occurrence of adverse reactions and interactions with other drugs or food. A significant role in
the mentioned activities should be played by the pharmacist, as the most accessible member of
the health team, who can, if necessary, refer the patient to a doctor for diagnosis, monitor the
effectiveness and safety of the therapy, and provide appropriate patient counseling.
AB  - Poremećaj funkcije tiroidne žlezde spada u najčešće endokrine poremećaje, posebno u ženskoj populaciji. Ukoliko se poremećaj ne ustanovi na vreme i ne leči adekvatno, kvalitet života pacijenta može biti narušen i može doći do dodatnih zdravstvenih problema, s obzirom na ključne uloge koje tireoidni hormoni imaju u organizmu. Stoga je neophodno podići svest o važnosti prepoznavanja simptoma koji ukazuju na potencijalni problem sa štitnom žlezdom, kao i moguće uzroke. Kod pacijenata koji su na terapiji levotiroksinom (hipotireoidizam) ili tiamazolom, karbimazolom ili propiltiouracilom (hipertireoidizam), potrebno je ukazati na značaj pravilne i redovne upotrebe lekova, uz sprovođenje pratećih nefarmakoloških mera, i ukazati na potencijal za pojavu neželjenih reakcija i interakcija sa drugim lekovima/hranom. Značajnu ulogu u navedenim aktivnostima bi trebalo da ima farmaceut, kao najdostupniji član zdravstvenog tima, koji može uputiti pacijenta lekaru radi postavljanje dijagnoze, pratiti efikasnost i bezbednost terapije, i pružiti pacijentu adekvatno savetovanje.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Role of pharmacists in management of patients with thyroid disorders
T1  - Uloga farmaceuta u zbrinjavanju pacijenta sa poremećajem rada tiroidne žlezde
VL  - 72
IS  - 5
SP  - 486
EP  - 502
DO  - 10.5937/arhfarm72-39948
ER  - 

@article{
author = "Homšek, Ana and Roganović, Maša and Kovačević, Milena and Jovanović, Marija",
year = "2022",
abstract = "Thyroid dysfunction is one of the most prevalent endocrine disorders, especially common
in female patients. If patients are not diagnosed in time or adequately treated, the patients’ quality
of life can be significantly impaired and additional health problems may occur, considering the
key roles of thyroid hormones in the body. Therefore, it is necessary to raise awareness about the
importance of recognition of symptoms that may indicate a potential problem with the thyroid
gland and help to identify possible causes. For patients who are already being treated with
levothyroxine (hypothyroidism), or thiamazole, carbimazole or propylthiouracil
(hyperthyroidism), it is necessary to point out the necessity of proper, regular use of the drugs and
implementation of accompanying nonpharmacological measures, as well as the potential for the
occurrence of adverse reactions and interactions with other drugs or food. A significant role in
the mentioned activities should be played by the pharmacist, as the most accessible member of
the health team, who can, if necessary, refer the patient to a doctor for diagnosis, monitor the
effectiveness and safety of the therapy, and provide appropriate patient counseling., Poremećaj funkcije tiroidne žlezde spada u najčešće endokrine poremećaje, posebno u ženskoj populaciji. Ukoliko se poremećaj ne ustanovi na vreme i ne leči adekvatno, kvalitet života pacijenta može biti narušen i može doći do dodatnih zdravstvenih problema, s obzirom na ključne uloge koje tireoidni hormoni imaju u organizmu. Stoga je neophodno podići svest o važnosti prepoznavanja simptoma koji ukazuju na potencijalni problem sa štitnom žlezdom, kao i moguće uzroke. Kod pacijenata koji su na terapiji levotiroksinom (hipotireoidizam) ili tiamazolom, karbimazolom ili propiltiouracilom (hipertireoidizam), potrebno je ukazati na značaj pravilne i redovne upotrebe lekova, uz sprovođenje pratećih nefarmakoloških mera, i ukazati na potencijal za pojavu neželjenih reakcija i interakcija sa drugim lekovima/hranom. Značajnu ulogu u navedenim aktivnostima bi trebalo da ima farmaceut, kao najdostupniji član zdravstvenog tima, koji može uputiti pacijenta lekaru radi postavljanje dijagnoze, pratiti efikasnost i bezbednost terapije, i pružiti pacijentu adekvatno savetovanje.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Role of pharmacists in management of patients with thyroid disorders, Uloga farmaceuta u zbrinjavanju pacijenta sa poremećajem rada tiroidne žlezde",
volume = "72",
number = "5",
pages = "486-502",
doi = "10.5937/arhfarm72-39948"
}

Homšek, A., Roganović, M., Kovačević, M.,& Jovanović, M.. (2022). Role of pharmacists in management of patients with thyroid disorders. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(5), 486-502.
https://doi.org/10.5937/arhfarm72-39948

Homšek A, Roganović M, Kovačević M, Jovanović M. Role of pharmacists in management of patients with thyroid disorders. in Arhiv za farmaciju. 2022;72(5):486-502.
doi:10.5937/arhfarm72-39948 .

Homšek, Ana, Roganović, Maša, Kovačević, Milena, Jovanović, Marija, "Role of pharmacists in management of patients with thyroid disorders" in Arhiv za farmaciju, 72, no. 5 (2022):486-502,
https://doi.org/10.5937/arhfarm72-39948 . .

TY  - CONF
AU  - Roganović, Maša
AU  - Cvetković, Mirjana
AU  - Gojković, Ivana
AU  - Spasojević, Brankica
AU  - Kostić, Mirjana
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4819
AB  - Introduction: Cyclosporine (CyA), an immunosuppressive agent, is mandatory part of post-transplantation therapy protocols. CyA shows large interindividual and intraindividual pharmacokinetic (PK) variability, has a narrow therapeutic range and several factors has already been identified as sources of variability. Proactive dosing strategies to achieve and maintain predefined CyA levels, via therapeutic drug monitoring (TDM), may prevent graft rejection and minimize serious side effects [1,2]. Data obtained during TDM can be used for describing PK model on both population and individual level while taking into account individual characteristics. Furthermore, that model could inform optimal CyA dosing via Bayesian-TDM approach.

Objectives: We aimed in developing CyA population PK model and address sources of PK variabilities in order to explain observable differences in the concentrations of the drug. In addition, the objective of the study is to assess the effect of PK on the response to CyA therapy using modelling approach. 

Methods: Data regarding dosage regimens, CyA blood concentrations, concomitant medications and laboratory findings of significance in kidney transplant paediatric patients were collected from their medical history. Drug concentration was measured in whole blood samples, and the samples were drawn before (Ctrough) and 2 hours after the morning dose (C2). Population pharmacokinetic analyses was performed using nonlinear mixed effects modelling software – NONMEM® (version 7.4) with first-order conditional estimation method with interaction (FOCE-I). NONMEM outputs were handled in R software (graphical diagnostics). We tried fitting one- and two-compartment to concentration-time data. Covariate model building was performed using stepwise covariate procedure (SCM). Covariates that were tested are age, weight (WT), serum creatinine levels (CR) haematocrit (HCT) (continuous covariates). Influence of categorical covariates was also examined – gender (GEND) and type of transplanted graft - live or cadaveric transplantation (TRANS). Model appropriateness has been performed using numerical and visual approaches.

Results: : In total, 58 patients aged 2-25 years (mean± sd: 12.46±0.78), mainly paediatrics (79.31% up to 18 years) were included in the analysis. We have analysed 496 concentrations obtained during up to one year post-transplant period. Mean values of C0 and C2 are 126.1±4.37 ng/ml and 825.8±20.32 ng/ml, respectively. One-compartment model with first order absorption best described the data. Typical values of clearance (CL), volume (V), and absorption rate constant (Ka) from covariate model were 14.2 L/h, 1.94 L/kg, 1.3 1/h, respectively. Tested PK parameter-covariate relations that caused the significant drop in objective function value are influence of WT, CR and HCT on CL, and WT on volume V. Interindividual variability (IIV) on CL and V, after inclusion of covariates was 22.6 % and 25.3% (in the base model the IIV was 33.5% and 36.5%, respectively). In the further analyses, population pharmacokinetic/pharmacodynamic (popPK/PD) will be developed.

Conclusions: The results regarding PK parameters are in accordance with a published study in a similar population (paediatric transplant patients) [3]. Knowing individual parameters values can help maximize the benefits of drug therapy and minimize side effects, which is a cornerstone of safe and effective therapy.


References:
[1] Midtvedt K. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2 Suppl):430S-433S. doi:10.1016/j.transproceed.2004.01.025.
[2] Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10. doi:10.3904/kjim.2009.24.1.1
[3] Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol. 2007;64(6):772-84. doi: 10.1111/j.1365-2125.2007.03003.x
C3  - Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe
T1  - Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4819
ER  - 

@conference{
author = "Roganović, Maša and Cvetković, Mirjana and Gojković, Ivana and Spasojević, Brankica and Kostić, Mirjana and Miljković, Branislava and Vučićević, Katarina",
year = "2021",
abstract = "Introduction: Cyclosporine (CyA), an immunosuppressive agent, is mandatory part of post-transplantation therapy protocols. CyA shows large interindividual and intraindividual pharmacokinetic (PK) variability, has a narrow therapeutic range and several factors has already been identified as sources of variability. Proactive dosing strategies to achieve and maintain predefined CyA levels, via therapeutic drug monitoring (TDM), may prevent graft rejection and minimize serious side effects [1,2]. Data obtained during TDM can be used for describing PK model on both population and individual level while taking into account individual characteristics. Furthermore, that model could inform optimal CyA dosing via Bayesian-TDM approach.

Objectives: We aimed in developing CyA population PK model and address sources of PK variabilities in order to explain observable differences in the concentrations of the drug. In addition, the objective of the study is to assess the effect of PK on the response to CyA therapy using modelling approach. 

Methods: Data regarding dosage regimens, CyA blood concentrations, concomitant medications and laboratory findings of significance in kidney transplant paediatric patients were collected from their medical history. Drug concentration was measured in whole blood samples, and the samples were drawn before (Ctrough) and 2 hours after the morning dose (C2). Population pharmacokinetic analyses was performed using nonlinear mixed effects modelling software – NONMEM® (version 7.4) with first-order conditional estimation method with interaction (FOCE-I). NONMEM outputs were handled in R software (graphical diagnostics). We tried fitting one- and two-compartment to concentration-time data. Covariate model building was performed using stepwise covariate procedure (SCM). Covariates that were tested are age, weight (WT), serum creatinine levels (CR) haematocrit (HCT) (continuous covariates). Influence of categorical covariates was also examined – gender (GEND) and type of transplanted graft - live or cadaveric transplantation (TRANS). Model appropriateness has been performed using numerical and visual approaches.

Results: : In total, 58 patients aged 2-25 years (mean± sd: 12.46±0.78), mainly paediatrics (79.31% up to 18 years) were included in the analysis. We have analysed 496 concentrations obtained during up to one year post-transplant period. Mean values of C0 and C2 are 126.1±4.37 ng/ml and 825.8±20.32 ng/ml, respectively. One-compartment model with first order absorption best described the data. Typical values of clearance (CL), volume (V), and absorption rate constant (Ka) from covariate model were 14.2 L/h, 1.94 L/kg, 1.3 1/h, respectively. Tested PK parameter-covariate relations that caused the significant drop in objective function value are influence of WT, CR and HCT on CL, and WT on volume V. Interindividual variability (IIV) on CL and V, after inclusion of covariates was 22.6 % and 25.3% (in the base model the IIV was 33.5% and 36.5%, respectively). In the further analyses, population pharmacokinetic/pharmacodynamic (popPK/PD) will be developed.

Conclusions: The results regarding PK parameters are in accordance with a published study in a similar population (paediatric transplant patients) [3]. Knowing individual parameters values can help maximize the benefits of drug therapy and minimize side effects, which is a cornerstone of safe and effective therapy.


References:
[1] Midtvedt K. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2 Suppl):430S-433S. doi:10.1016/j.transproceed.2004.01.025.
[2] Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10. doi:10.3904/kjim.2009.24.1.1
[3] Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol. 2007;64(6):772-84. doi: 10.1111/j.1365-2125.2007.03003.x",
journal = "Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe",
title = "Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4819"
}

Roganović, M., Cvetković, M., Gojković, I., Spasojević, B., Kostić, M., Miljković, B.,& Vučićević, K.. (2021). Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data. in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
https://hdl.handle.net/21.15107/rcub_farfar_4819

Roganović M, Cvetković M, Gojković I, Spasojević B, Kostić M, Miljković B, Vučićević K. Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data. in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_4819 .

Roganović, Maša, Cvetković, Mirjana, Gojković, Ivana, Spasojević, Brankica, Kostić, Mirjana, Miljković, Branislava, Vučićević, Katarina, "Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data" in Page. Abstracts of the Annual Meeting of the Population Approach Group in Europe (2021),
https://hdl.handle.net/21.15107/rcub_farfar_4819 .

TY  - JOUR
AU  - Roganović, Maša
AU  - Homšek, Ana
AU  - Jovanović, Marija
AU  - Topić-Vučenović, Valentina
AU  - Ćulafić, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3960
AB  - Due to frequent clinical trial failures and consequently fewer new drug approvals, the need
for improvement in drug development has, to a certain extent, been met using model-based drug
development. Pharmacometrics is a part of pharmacology that quantifies drug behaviour,
treatment response and disease progression based on different models (pharmacokinetic - PK,
pharmacodynamic - PD, PK/PD models, etc.) and simulations. Regulatory bodies (European
Medicines Agency, Food and Drug Administration) encourage the use of modelling and
simulations to facilitate decision-making throughout all drug development phases. Moreover, the
identification of factors that contribute to variability provides a basis for dose individualisation in
routine clinical practice. This review summarises current knowledge regarding the application of
pharmacometrics in drug development and clinical practice with emphasis on the population
modelling approach.
AB  - Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice
T1  - Koncept i upotreba populacionih farmakokinetičkih i farmakokinetičko/farmakodinamičkih modela u razvoju leka i kliničkoj praksi
VL  - 71
IS  - 4
SP  - 336
EP  - 353
DO  - 10.5937/arhfarm71-32901
ER  - 

@article{
author = "Roganović, Maša and Homšek, Ana and Jovanović, Marija and Topić-Vučenović, Valentina and Ćulafić, Milica and Miljković, Branislava and Vučićević, Katarina",
year = "2021",
abstract = "Due to frequent clinical trial failures and consequently fewer new drug approvals, the need
for improvement in drug development has, to a certain extent, been met using model-based drug
development. Pharmacometrics is a part of pharmacology that quantifies drug behaviour,
treatment response and disease progression based on different models (pharmacokinetic - PK,
pharmacodynamic - PD, PK/PD models, etc.) and simulations. Regulatory bodies (European
Medicines Agency, Food and Drug Administration) encourage the use of modelling and
simulations to facilitate decision-making throughout all drug development phases. Moreover, the
identification of factors that contribute to variability provides a basis for dose individualisation in
routine clinical practice. This review summarises current knowledge regarding the application of
pharmacometrics in drug development and clinical practice with emphasis on the population
modelling approach., Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice, Koncept i upotreba populacionih farmakokinetičkih i farmakokinetičko/farmakodinamičkih modela u razvoju leka i kliničkoj praksi",
volume = "71",
number = "4",
pages = "336-353",
doi = "10.5937/arhfarm71-32901"
}

Roganović, M., Homšek, A., Jovanović, M., Topić-Vučenović, V., Ćulafić, M., Miljković, B.,& Vučićević, K.. (2021). Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 71(4), 336-353.
https://doi.org/10.5937/arhfarm71-32901

Roganović M, Homšek A, Jovanović M, Topić-Vučenović V, Ćulafić M, Miljković B, Vučićević K. Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice. in Arhiv za farmaciju. 2021;71(4):336-353.
doi:10.5937/arhfarm71-32901 .

Roganović, Maša, Homšek, Ana, Jovanović, Marija, Topić-Vučenović, Valentina, Ćulafić, Milica, Miljković, Branislava, Vučićević, Katarina, "Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice" in Arhiv za farmaciju, 71, no. 4 (2021):336-353,
https://doi.org/10.5937/arhfarm71-32901 . .

TY  - CONF
AU  - Milenković, Branislava
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3737
AB  - Introduction: Pharmacists have a significant role in improving patient inhaler technique (HK. Reddel, et al. Eur Respir J 2008;32: 812; Alismail A, et al. Respir Care 2016;61:593). Hence, it is crucial for pharmacists to develop skills in educating patients on the correct use of inhalers.

Aims: The aim of the study was to evaluate the effectiveness of an educational intervention on the pharmacists’ inhaler technique demonstration skills.

Methods: The study was performed during the community pharmacists’ training classes in 2019. Demonstration of correct inhaler technique was performed for metered-dose (MDI), dry powder (DPI) and soft mist inhalers (SMI). All participants were instructed about correct technique and given placebo inhalers. After the demonstration, they were assessed on the use of each of these devices. The pharmacists were given a 1-point score for each step (1-preparation, 2-expiration, 3-inhalation, 4-holding breath) performed correctly.

Results: All participants (108) showed improved inhaler technique after training (3.8±0.5 points). Friedman test showed a significant difference in achieved score depending on the type of the inhaler (p<0.05) and the lowest was with MDI. After education, 29.6% of participants had a problem with coordination of dose release and inhalation using MDIs. Only 4.6% made an error in step 3 for DPIs (strong and fast inhalation). None of the participants made an error in the same step for SMI (slow and deep inhalation).

Conclusion: This method of inhaler technique training is sufficient to provide the skills to the pharmacist in educating patients about the correct use. However these results indicate that there was a difference in the ability to use different inhalers.
PB  - European Respiratory Society
C3  - European Respiratory Journal
T1  - Inhaler technique training of community pharmacists and common errors
VL  - 56
IS  - Suppl. 64
DO  - 10.1183/13993003.congress-2020.3174
ER  - 

@conference{
author = "Milenković, Branislava and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2020",
abstract = "Introduction: Pharmacists have a significant role in improving patient inhaler technique (HK. Reddel, et al. Eur Respir J 2008;32: 812; Alismail A, et al. Respir Care 2016;61:593). Hence, it is crucial for pharmacists to develop skills in educating patients on the correct use of inhalers.

Aims: The aim of the study was to evaluate the effectiveness of an educational intervention on the pharmacists’ inhaler technique demonstration skills.

Methods: The study was performed during the community pharmacists’ training classes in 2019. Demonstration of correct inhaler technique was performed for metered-dose (MDI), dry powder (DPI) and soft mist inhalers (SMI). All participants were instructed about correct technique and given placebo inhalers. After the demonstration, they were assessed on the use of each of these devices. The pharmacists were given a 1-point score for each step (1-preparation, 2-expiration, 3-inhalation, 4-holding breath) performed correctly.

Results: All participants (108) showed improved inhaler technique after training (3.8±0.5 points). Friedman test showed a significant difference in achieved score depending on the type of the inhaler (p<0.05) and the lowest was with MDI. After education, 29.6% of participants had a problem with coordination of dose release and inhalation using MDIs. Only 4.6% made an error in step 3 for DPIs (strong and fast inhalation). None of the participants made an error in the same step for SMI (slow and deep inhalation).

Conclusion: This method of inhaler technique training is sufficient to provide the skills to the pharmacist in educating patients about the correct use. However these results indicate that there was a difference in the ability to use different inhalers.",
publisher = "European Respiratory Society",
journal = "European Respiratory Journal",
title = "Inhaler technique training of community pharmacists and common errors",
volume = "56",
number = "Suppl. 64",
doi = "10.1183/13993003.congress-2020.3174"
}

Milenković, B., Roganović, M., Kovačević, M., Ćulafić, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2020). Inhaler technique training of community pharmacists and common errors. in European Respiratory Journal
European Respiratory Society., 56(Suppl. 64).
https://doi.org/10.1183/13993003.congress-2020.3174

Milenković B, Roganović M, Kovačević M, Ćulafić M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Inhaler technique training of community pharmacists and common errors. in European Respiratory Journal. 2020;56(Suppl. 64).
doi:10.1183/13993003.congress-2020.3174 .

Milenković, Branislava, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Inhaler technique training of community pharmacists and common errors" in European Respiratory Journal, 56, no. Suppl. 64 (2020),
https://doi.org/10.1183/13993003.congress-2020.3174 . .